All News

Found 316 articles

• Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

  5/31/2022

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the Phase 3 pivotal trial of UPLIZNA in NMOSD illustrating the treatment’s effectiveness among patients with different genetic make-ups.

• Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

  5/31/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that the Biologics License Application (“BLA”) for OMBLASTYS® (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration (“FDA”).

• 

  Takeda, Seagen and Y-mAbs Highlight Data in Difficult Cancers Ahead of ASCO

  5/27/2022

  Two therapies for different cancers are moving forward in development following positive outcomes in their clinical trials ahead of the ASCO's annual meeting in early June 2022.

• Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/26/2022

  Genmab A/S announced that multiple abstracts evaluating several investigational medicines in the company’s pipeline, or created using Genmab’s innovative drug development platforms, will be presented at the 2022 American Society of Clinical Oncology Annual Meeting, being held at McCormick Place, in Chicago, IL, and virtually, June 3-7.

• Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

  5/26/2022

  Y-mAbs Therapeutics, Inc. announced that Dr. Shakeel Modak, MD from Memorial Sloan Kettering will present results from the naxitamab-based chemoimmunotherapy trial in patients with chemoresistant high-risk neuroblastoma, at the American Society of Clinical Oncology Annual Meeting to be held June 3-7, 2022.

• New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab

  5/18/2022

  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system.

• Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

  5/18/2022

  Scilex Holding Company (“Scilex”), announced dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with acute LBP.

• Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

  5/12/2022

  Genmab A/S announced that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.

• AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

  5/12/2022

  AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and the European Hematology Association (EHA) Congress (June 9-17).

• Genmab Announces Financial Results for the First Quarter of 2022

  5/11/2022

  Genmab Announces Financial Results for the First Quarter of 2022.

• Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

  5/5/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.

• Mechanical Ventilator Market Size to Hit US$ 5.22 Bn by 2030

  5/4/2022

  The global mechanical ventilator market was estimated at USD 4.79 billion in 2020 and is predicted to hit around USD 5.22 billion by 2030 with a CAGR of 4.9% from 2022 to 2030.

• Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

  5/3/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial markets.

• Biopharmaceutical CMO and CRO Market Size to Hit US$ 60.1 BN by 2030

  5/3/2022

  The global biopharmaceutical CMO and CRO market was valued at USD 30.1 billion in 2020 and is expected to rake around USD 60.1 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030.

• Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

  4/27/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the following executive management changes: Dr. Claus Moller has stepped down from his positions as Chief Executive Officer and Board Member effective immediately.

• Cancer Immunotherapy Market Size to Worth Around US$ 130.6 BN by 2030

  4/26/2022

  According to Report, the global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030 and is anticipated to grow at a CAGR of 10.6% from 2021 to 2030.

• Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

  4/23/2022

  Nektar Therapeutics announced that collaborators from the Cairo Laboratory at New York Medical College presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor activities of different CAR-T therapies in a variety of cancer preclinical models.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

  4/19/2022

  Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD1,856million in the first quarter of 2022.

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

  4/13/2022

  Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors.

• Y-mAbs Announces Presentation of SADA Technology at AACR

  4/8/2022

  Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at the AACR Annual Meeting 2022, which takes place in New Orleans, Louisiana from April 8-13, 2022.